Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II.

We report the production and characterization of four monoclonal antibodies (MAbs) against human urotensin-II (hU-II). The antibodies were raised against human hU-II, which contains the C-terminus cyclic ring (CFWKYC) that is conserved across species. Multiple selection assays were applied to ensure antibody potency and reactivity against the ring structure. The MAbs reacted via ELISA with hU-II bound to plastic, immunoprecipitated [(125)I-Y(9)] hU-II, bound to biotinylated hU-II in BIAcore analysis and, by Western analysis, recognized the full-length human preprourotensin-II expressed in transfected HEK293 cells. All four MAbs cross-reacted with porcine A, porcine B, rat, mouse, and goby U-II in ELISA. By competitive RIA, hU-II(5-11) (identical to the C-terminus of goby U-II) reacted equivalently to hU-II and goby U-II. The IC(50)s were 0.8 nM for one MAb and 1.6 nM for the others. All four MAbs reacted 15-fold less potently with hU-II(5-10) and 50-fold less potently with hU-II(5-10) amide. Thus, the ring structure and terminal Val/Ile comprise the binding site for this group of MAbs. This panel of antibodies could be useful tools to help delineate the biology and pharmacology of U-II. They may also be of diagnostic value in monitoring hU-II in body fluids.

[1]  S. Ito,et al.  Role of urotensin II in patients on dialysis , 2001, The Lancet.

[2]  J. A. Payne,et al.  Rapid development of affinity matured monoclonal antibodies using RIMMS. , 1997, Hybridoma.

[3]  Yumiko Saito,et al.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.

[4]  S. Stimpson,et al.  Neutralizing IGF-1 monoclonal antibody with cross-species reactivity. , 1997, Hybridoma.

[5]  A. Zeiger,et al.  Immunochemistry of a synthetic peptidoglycan-precursor pentapeptide. , 1973, Biochemistry.

[6]  J. Conlon,et al.  Post‐translational processing of prepro‐urotensin II , 1990, FEBS letters.

[7]  I. Squire,et al.  Plasma Urotensin in Human Systolic Heart Failure , 2002, Circulation.

[8]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[9]  T. Klabunde,et al.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.

[10]  N. Aiyar,et al.  Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey , 2002, British journal of pharmacology.

[11]  S. Douglas,et al.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.

[12]  S. Douglas,et al.  Congestive heart failure and expression of myocardial urotensin II , 2002, The Lancet.

[13]  T. Sauerbruch,et al.  Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. , 2001, Journal of hepatology.

[14]  H. Itoh,et al.  Functional receptors for fish neuropeptide urotensin II in major rat arteries. , 1988, European journal of pharmacology.

[15]  M Kurihara,et al.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). , 1999, Biochemical and biophysical research communications.

[16]  S. Douglas,et al.  Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  A. Richards,et al.  Plasma urotensin II in heart failure , 2002, The Lancet.

[18]  H. Vaudry,et al.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Webb,et al.  High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. , 2002, Cardiovascular research.

[20]  Jilly F. Evans,et al.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. , 1999, Biochemical and biophysical research communications.

[21]  H. Vaudry,et al.  Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives , 1997, Regulatory Peptides.